Penumbra (BSP:P2NB34) Cyclically Adjusted Revenue per Share: R$0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:P2NB34 Penumbra Inc BSP:P2NB34
21 GF Score
Price R$55.13
GF Value R$57.24
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Cyclically Adjusted Revenue per Share?

Penumbra BSP:P2NB34 21 Cyclically Adjusted Revenue per Share is R$0.00 as of Jun. 2026. GuruFocus rates BSP:P2NB34 with a GF Score™ of 21/100 and a GF Value™ of R$57.24 (Fairly Valued). The stock has 1 warning sign investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Penumbra's adjusted revenue per share for the three months ended in Jun. 2026 was R$50.506. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Penumbra's average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-05), Penumbra's current stock price is R$55.13. Penumbra's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$0.00. Penumbra's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.11.


Penumbra  (BSP:P2NB34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Penumbra Cyclically Adjusted Revenue per Share Related Terms


Penumbra Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Penumbra's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Cyclically Adjusted Revenue per Share Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Penumbra Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BSP:P2NB34 vs GMED, GKOS, BIO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Penumbra's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Penumbra's Cyclically Adjusted PS Ratio falls into.


BSP:P2NB34
21GF Score
Penumbra Inc BSP:P2NB34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Penumbra's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=50.506/333.9520*333.9520
=50.506

Current CPI (Jun. 2026) = 333.9520.

Penumbra Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.475 241.428 8.956
201612 7.252 241.432 10.031
201703 7.243 243.801 9.921
201706 7.995 244.955 10.900
201709 7.370 246.819 9.972
201712 7.364 246.524 9.976
201803 9.376 249.554 12.547
201806 11.448 251.989 15.172
201809 13.413 252.439 17.744
201812 11.122 251.233 14.784
201903 13.622 254.202 17.896
201906 14.288 256.143 18.628
201909 15.844 256.759 20.607
201912 16.410 256.974 21.326
202003 18.453 258.115 23.875
202006 15.405 257.797 19.956
202009 22.531 260.280 28.908
202012 23.614 260.474 30.275
202103 25.403 264.877 32.028
202106 24.654 271.696 30.303
202109 26.684 274.310 32.486
202112 29.773 278.802 35.662
202203 26.213 287.504 30.448
202206 27.845 296.311 31.382
202209 29.549 296.808 33.247
202212 30.510 296.797 34.329
202303 32.178 301.836 35.602
202306 32.378 305.109 35.439
202309 34.118 307.789 37.018
202312 35.479 306.746 38.626
202403 35.231 312.332 37.670
202406 41.570 314.175 44.187
202409 42.552 315.301 45.069
202412 47.006 315.605 49.739
202503 47.658 319.799 49.767
202506 47.968 322.561 49.662
202509 48.399 324.800 49.763
202512 53.344 324.054 54.973
202603 49.561 330.213 50.122
202606 50.506 333.952 50.506

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$0.00 mean?
Penumbra (BSP:P2NB34) has a Cyclically Adjusted Revenue per Share of R$0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors.
Is Penumbra's Cyclically Adjusted Revenue per Share too high?
Penumbra's current Cyclically Adjusted Revenue per Share is R$0.00. Overall, Penumbra has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Cyclically Adjusted Revenue per Share compare to GMED and GKOS?
Penumbra's Cyclically Adjusted Revenue per Share of R$0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors. Penumbra's current Cyclically Adjusted Revenue per Share is R$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (BSP:P2NB34) is currently considered Fairly Valued. The stock's GF Value™ is R$57.24, compared to a current price of R$55.13 — trading 3.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$0.00. Penumbra's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Penumbra (BSP:P2NB34), the current Cyclically Adjusted Revenue per Share is R$0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (BSP:P2NB34) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of R$55.13 is trading 3.7% below its estimated GF Value™ of R$57.24. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for BSP:P2NB34:

  • Cyclically Adjusted Revenue per Share: R$0.00
  • GF Value™: R$57.24 vs. price of R$55.13 (3.7% below fair value)
  • GF Score™: 21/100 with 1 warning sign

No single metric tells the full story. See the BSP:P2NB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Penumbra Business Description

Other Exchanges PEN:USA
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
21GF Score

Get the complete analysis for BSP:P2NB34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$55.13
Price
R$57.24
GF Value